Information on how to access Mylotarg™▼ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.
Median Event Free Survival* was significantly longer with MYLOTARG + chemotherapy vs chemotherapy alone1
Figure adapted from MYLOTARG Summary of Product Characteristics
* Defined as the time from randomisation to the date of assessment of the response (if CR or CRp had not been achieved), relapse or death.
CHEMO, chemotherapy; CI, confidence interval; CR, complete remission; CRp, complete remission with incomplete platelet recovery; EFS, event-free survival; HR, hazard ratios; mo, months; MYLO, MYLOTARG
CHEMO, chemotherapy; CI, confidence interval; CR, complete remission; CRp, complete remission with incomplete platelet recovery; EFS, event-free survival; HR, hazard rarios; mo, months; MYLO, MYLOTARG
Watch Professor Robert Hills discuss the key clinical data from the pivotal ALFA study
Watch Dr Eleni Tholouli discuss the NICE approval for MYLOTARG and efficacy data using the ALFA schedule
Order a hard copy
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020